Q1 Earnings vs. Estimates

• EPS: Reported $1.79, beating the $1.67 consensus by $0.12.

• Revenue: $9.89 B vs. $10.99 B estimate—a 10% shortfall.

• Key Drivers: Specialty care and vaccines drove margin strength, but generics and consumer health underperformed.

Stock Performance and Analyst Sentiment

• Closing Price: $53.02 per ADR

• Momentum: +1.0% over 3 months; +7.4% over 12 months

• Analyst Revisions: Mixed—positive EPS revisions offset by cautious revenue outlook tweaks.

Financial Health Snapshot

Sanofi's robust balance sheet underpins its resilience:

• Profit Margins: Holding up despite top-line pressures

• Leverage: Moderate debt with ample liquidity

Outlook and Investor Takeaways

1. Q2 Guidance: Look for updated sales forecasts on May 7 earnings call.

2. Pipeline Catalysts: Late-stage readouts in diabetes and immunology.

3. Cost Synergies: Progress on recent M&A integrations could bolster margins.

Track Sanofi's Past Earnings and Market Reactions

For detailed historical EPS and revenue surprises—and how Sanofi's stock reacted—use the
🔗 Historical Earnings API
from Financial Modeling Prep. This API delivers past earnings versus estimates, enabling you to analyze patterns in consensus beats, misses, and stock price responses.